We are live on
!
Find out more
Kiniksa Pharmaceuticals
KNSA
KNSA
132 hedge funds and large institutions have $340M invested in Kiniksa Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 56 increasing their positions, 33 reducing their positions, and 16 closing their positions.
New
Increased
Maintained
Reduced
Closed
124% more call options, than puts
Call options by funds: $4.83M | Put options by funds: $2.16M
70% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 33
44% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 16
6% more funds holding
Funds holding: 125 → 132 (+7)
4.08% more ownership
Funds ownership: 87.31% → 91.39% (+4.1%)
24% less capital invested
Capital invested by funds: $444M → $340M (-$105M)
Holders
132
Holders Change
+7
Holders Change %
+5.6%
% of All Funds
2.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
23
Increased
56
Reduced
33
Closed
16
Calls
$4.83M
Puts
$2.16M
Net Calls
+$2.67M
Net Calls Change
-$1.53M
Top Buyers
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$15.9M |
| 2 |
Morgan Stanley
New York
|
+$9.49M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$8.68M |
| 4 |
State Street
Boston,
Massachusetts
|
+$4.05M |
| 5 |
Envestnet Asset Management
Chicago,
Illinois
|
+$3.59M |
Top Sellers
| 1 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$21.2M |
| 2 |
Goldman Sachs
New York
|
-$7.83M |
| 3 |
HIM
Hillsdale Investment Management
Toronto,
Ontario, Canada
|
-$3.66M |
| 4 |
LPC
Lion Point Capital
New York
|
-$3.07M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.02M |
